about
Biomarkers of residual disease, disseminated tumor cells, and metastases in the MMTV-PyMT breast cancer modelEpithelial cell dissemination and readhesion: analysis of factors contributing to metastasis formation in breast cancerMathematical model identifies blood biomarker-based early cancer detection strategies and limitationsIntravital imaging reveals new ancillary mechanisms co-opted by cancer cells to drive tumor progressionGlioblastoma Circulating Cells: Reality, Trap or Illusion?Molecular interactions in the development of brain metastasesMicrometastatic cancer cells in lymph nodes, bone marrow, and blood: Clinical significance and biologic implicationsInteractions between tumor cells and microenvironment in breast cancer: a new opportunity for targeted therapyMechanisms of disseminated cancer cell dormancy: an awakening fieldOsteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche.Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motionTumor cell dormancyDormancy of growth-stunted malignant melanoma: sustainable and smoldering patternsModulation of CD44 Activity by A6-PeptideRole of MTA2 in human cancerIdentification of novel drugs to target dormant micrometastasesMatrix rigidity regulates cancer cell growth by modulating cellular metabolism and protein synthesis.Chemotaxis in cancerBrain metastases from breast cancer: lessons from experimental magnetic resonance imaging studies and clinical implications.Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasisAssessing the risk of second malignancies after modern radiotherapySpatial-temporal FUCCI imaging of each cell in a tumor demonstrates locational dependence of cell cycle dynamics and chemoresponsivenessProstate cancer xenografts engineered from 3D precision-porous poly(2-hydroxyethyl methacrylate) hydrogels as models for tumorigenesis and dormancy escape.Tumor acidity as evolutionary spite.Evolution of Tumor Metabolism might Reflect Carcinogenesis as a Reverse Evolution process (Dismantling of Multicellularity).Prospective identification of glioblastoma cells generating dormant tumors.Metastasis as a therapeutic target in prostate cancer: a conceptual framework.Structural ECM components in the premetastatic and metastatic niche.Immunotherapy using slow-cycling tumor cells prolonged overall survival of tumor-bearing mice.Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin SFunctional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse.Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cellsInvading cancer cells are predominantly in G0/G1 resulting in chemoresistance demonstrated by real-time FUCCI imagingPulmonary resection and systemic lymph node dissection in a patient with breast cancer who had a 33-year disease-free interval.An in vitro system to study tumor dormancy and the switch to metastatic growth.ERK1/2 and p38α/β signaling in tumor cell quiescence: opportunities to control dormant residual disease.VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors.Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in miceMonitoring dynamic interactions between breast cancer cells and human bone tissue in a co-culture model.Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery
P2860
Q21090788-BD74E894-8884-47F6-9E6D-12D1AC5C6F3EQ24606925-35252FF0-FC95-444C-9D1B-2CC346AF2175Q24614865-D4669948-A40B-4A0F-AA63-D3CB78F0260AQ26745311-6B1D809D-E1F9-4A9D-9C46-387C3F2EE78DQ26823823-F6221AD3-03BA-4C4D-AB0D-3B5847101538Q26865865-FF31C34C-A7F5-49A5-BBFE-F1337B0DACD9Q26996059-0DC7E591-E003-4E6B-8BC9-9F68A7E7EB5BQ27012888-7EF49E82-0282-487B-93CF-20E47B9F7FD0Q27027015-D7185DDF-28C9-42DC-A618-388FD3C4A8C4Q27316833-1B918C9B-AACE-4302-A218-450E1785AA51Q28066285-B67CD022-E6D8-4D4A-8C0C-BC0B7DBA23E2Q28073065-FD5D8564-0839-41FB-AB49-3BA566B47782Q28083204-302289EC-F3F6-4558-BBE2-061F88B29CB0Q28085166-4C5F13FE-6024-46F2-B53F-32BAFDFA5ABDQ28251565-74B4A970-622E-41F4-B2B0-80D17983ACCDQ28394296-20925E07-FEF4-4978-8FC8-C85ACBF23F06Q30426836-3C051AB1-084F-4229-9BC9-C59A354BBF13Q30578627-926BFEE8-DF34-43BB-9D55-D0A0340C7293Q30708273-B09507DA-68B9-4443-80A7-F69DD73E860DQ33798322-3A428B71-B874-4328-94BB-62BB031A16A1Q33914324-7C2DCD0E-913A-41E4-8ACB-048EE883302BQ33952918-899050C6-C69C-45D0-AF41-41B058D1BE6FQ34053377-66BF3A23-E130-4220-B799-66106805E713Q34390027-AEF7F60A-C471-4EBD-8545-DB1457D59814Q34390032-B1F2E550-0BB5-47F1-90C4-C2F08A96D1D6Q34412360-87262FD6-4670-43FE-87D5-6EFB54F2130FQ34448162-52091A59-856F-48F1-A9A7-1082BD4C3F80Q34521147-B845B7CB-D5A2-4CCC-BB65-A721538779A2Q34523894-6047A659-A967-4BCE-8B44-B1F9F9ACC688Q34599128-37F6456C-EF48-4282-A7CE-0312BD9FF79CQ34764685-7780AB56-EF4A-4EC4-817F-C8316ADA3674Q34773140-B2317A63-F17C-43CC-A6CA-4610A28C94FCQ35098274-CEECD6BD-0F6E-428D-8C93-2F4B0C163437Q35491750-1082EAAA-9892-43D5-B9C5-BCDAF1C4099FQ35536415-D38C203E-3D5F-4EBD-A9EA-92261FB7447BQ35579435-842A448B-5B5E-4817-A193-DA33DCA67321Q35621527-B6CF8377-2C7A-4AF9-B386-D95647F99037Q35640579-07E1F99E-CF9E-4452-9F89-A627C454EB4FQ35801397-2261022E-B370-4D7D-BBCC-536BF3CCCAFDQ35872080-A55167D7-E6BE-46D2-BC4C-F31F94D1C8BE
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Does tumour dormancy offer a therapeutic target?
@en
Does tumour dormancy offer a therapeutic target?
@nl
type
label
Does tumour dormancy offer a therapeutic target?
@en
Does tumour dormancy offer a therapeutic target?
@nl
prefLabel
Does tumour dormancy offer a therapeutic target?
@en
Does tumour dormancy offer a therapeutic target?
@nl
P2860
P356
P1476
Does tumour dormancy offer a therapeutic target?
@en
P2093
Paul E Goss
P2860
P2888
P304
P356
10.1038/NRC2933
P407
P577
2010-11-04T00:00:00Z